Ohio Public Employees Retirement System (OPERS)
ALXN

Ohio Public Employees Retirement System (OPERS)’s Alexion Pharmaceuticals ALXN Stock Holding History

Ohio Public Employees Retirement System (OPERS)’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-129,791
Closed -$23.8M – 2025
2021
Q2 		$23.8M Buy
129,791
+12,953
+11% +$2.22M 0.08% 220
2021
Q1 		$17.9M Buy
116,838
+8,443
+8% +$1.31M 0.07% 243
2020
Q4 		$16.9M Buy
108,395
+22,825
+27% +$2.93M 0.08% 229
2020
Q3 		$9.79M Buy
85,570
+3,416
+4% +$369K 0.05% 293
2020
Q2 		$9.22M Sell
82,154
-34,992
-30% -$3.71M 0.05% 312
2020
Q1 		$10.5M Sell
117,146
-8,479
-7% -$832K 0.07% 244
2019
Q4 		$13.6M Sell
125,625
-2,890
-2% -$309K 0.07% 250
2019
Q3 		$12.6M Buy
128,515
+564
+0.4% +$63.6K 0.07% 276
2019
Q2 		$16.8M Sell
127,951
-7,234
-5% -$932K 0.09% 225
2019
Q1 		$18.3M Buy
135,185
+558
+0.4% +$69.4K 0.1% 213
2018
Q4 		$13.1M Sell
134,627
-6,519
-5% -$771K 0.08% 242
2018
Q3 		$19.6M Sell
141,146
-2,115
-1% -$265K 0.1% 211
2018
Q2 		$17.8M Sell
143,261
-1,725
-1% -$202K 0.09% 229
2018
Q1 		$16.2M Sell
144,986
-8,960
-6% -$1.07M 0.08% 240
2017
Q4 		$18.4M Buy
153,946
+2,676
+2% +$326K 0.09% 229
2017
Q3 		$21.2M Buy
151,270
+107
+0.1% +$14.5K 0.11% 206
2017
Q2 		$18.4M Buy
151,163
+2,394
+2% +$279K 0.1% 221
2017
Q1 		$18M Buy
148,769
+242
+0.2% +$31.2K 0.1% 226
2016
Q4 		$19.4M Buy
148,527
+249
+0.2% +$30.5K 0.11% 209
2016
Q3 		$18.2M Buy
148,278
+188
+0.1% +$24.2K 0.11% 206
2016
Q2 		$17.3M Sell
148,090
-511
-0.3% -$72.5K 0.11% 211
2016
Q1 		$20.7M Sell
148,601
-8,385
-5% -$1.23M 0.14% 171
2015
Q4 		$29.9M Sell
156,986
-1,013
-0.6% -$177K 0.18% 124
2015
Q3 		$24.7M Buy
157,999
+399
+0.3% +$72.8K 0.16% 152
2015
Q2 		$28.5M Buy
157,600
+13,018
+9% +$2.25M 0.16% 148
2015
Q1 		$25.1M Buy
144,582
+495
+0.3% +$89.6K 0.14% 169
2014
Q4 		$26.7M Sell
144,087
-74
-0.1% -$13.7K 0.16% 151
2014
Q3 		$23.9M Sell
144,161
-7,462
-5% -$1.23M 0.14% 164
2014
Q2 		$23.7M Buy
151,623
+91,462
+152% +$14.4M 0.13% 174
2014
Q1 		$9.15M Sell
60,161
-10,838
-15% -$1.72M 0.05% 361
2013
Q4 		$9.45M Buy
70,999
+9,772
+16% +$1.17M 0.05% 386
2013
Q3 		$7.11M Buy
61,227
+2,607
+4% +$286K 0.04% 477
2013
Q2 		$5.41M Buy
+58,620
New +$5.65M 0.03% 521

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Ohio Public Employees Retirement System (OPERS)'s ALXN Position: Q3 2021 in Review

Ohio Public Employees Retirement System (OPERS) sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 129,791 shares — an estimated $23.8M sold.

Ohio Public Employees Retirement System (OPERS) first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $29.9M in Q4 2015. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Ohio Public Employees Retirement System (OPERS) reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Ohio Public Employees Retirement System (OPERS) sold 129,791 Alexion Pharmaceuticals shares in Q3 2021, an estimated $23.8M.
  • Ohio Public Employees Retirement System (OPERS) first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Ohio Public Employees Retirement System (OPERS)'s Alexion Pharmaceuticals position peaked at $29.9M in Q4 2015.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Ohio Public Employees Retirement System (OPERS)'s 13F filing for Q3 2021, filed 15 Nov 2021.